IPO Date: Nov 21 to Nov 25 2025
Listing Date: Nov 28 2025
(i)Capital expenditure towards procurement of machinery for our production line located at Nandesari Facility I; and(ii)General corporate purposes.
...
edicated to contributing to the global healthcare ecosystem. We leverage our inhouse developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending in an effort to drive innovation in our operations. We have established a presence in both, domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.We are one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual manufacturing capacity of 65,579 metric tons (“MT”), as of December 31, 2024. (Source: F&S Report) As of the same date, one of our Manufacturing Facilities has been approved by the United States Food and Drug Administration (“USFDA”) for the manufacture of mineral-based ingredients. We are one of the largest exporters of mineral ingredients for pharmaceutical, food and nutrition industries from India to global markets in terms of volume of products exported during 2024 as of December 31, 2024. (Source: F&S Report) We were the only company in India and one of nine companies globally with certification of suitability issued by the Council of Europe (“CEP”) and written confirmation certification for sale of calcium carbonate as an active pharmaceutical ingredient (“API”) in the European Union as of December 31, 2024. (Source: F&S Report) We are one of the pioneers in India to introduce a product range of liposomal ingredients for nutrient absorption and stability. Read MoreMUFG Intime India Pvt Ltd.
Posted on Jan 7th
Sundaram Brake Linings informs about certificate
Posted on Jan 7th
India, Luxembourg can enhance bilateral cooperation in multiple areas: Jaishankar
Posted on Jan 6th
Yajur Fibres coming with IPO to raise Rs 120 crore
Posted on Jan 6th
Currency futures for January expiry trade stronger with 0.21% increase in OI
The issue size of Sudeep Pharma Ltd. IPO is ₹594.81 - 626.50 crore.
The Sudeep Pharma Ltd. IPO opens for subscription on 2025-11-21 and closes on 2025-11-25.
The price range of Sudeep Pharma Ltd. IPO is ₹563.00 to ₹593.00.
The lot size of Sudeep Pharma Ltd. IPO is 25 shares.
The registrar of Sudeep Pharma Ltd. IPO is MUFG Intime India Pvt Ltd..
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.